Drug
tirzepatide
Marketed as ZEPBOUND.
Generic name
tirzepatide
Brand names
ZEPBOUND
First FDA approval
2023-11-08
Drug class
GLP-1 receptor agonists
Patient assistance program
Lilly Cares
FDA approval history
| FDA ID | Brand | Approval date | Manufacturer |
|---|---|---|---|
| NDA217806 | ZEPBOUND | 2023-11-08 | ELI LILLY AND CO |
Manufacturers
ELI LILLY AND CO
Common denial patterns
- Weight-loss exclusion (Zepbound)
- Step therapy requiring GLP-1 first
- Quantity limit
Specific notes
Sold as Mounjaro (T2D) and Zepbound (chronic weight management). Dual GIP/GLP-1 receptor agonist.
Manufacturer patient assistance
Lilly Cares: https://www.lillycares.com
Frequently asked questions
Why does insurance commonly deny tirzepatide?
Weight-loss exclusion (Zepbound); Step therapy requiring GLP-1 first; Quantity limit.
When was tirzepatide FDA approved?
Earliest FDA approval on record: 2023-11-08.
What brand names are sold as tirzepatide?
ZEPBOUND.
Is there a patient assistance program for tirzepatide?
Yes — Lilly Cares at https://www.lillycares.com.
What's specific to tirzepatide?
Sold as Mounjaro (T2D) and Zepbound (chronic weight management). Dual GIP/GLP-1 receptor agonist.
Related
Sources
Appeal a tirzepatide denial
Upload your denial — DenialHelp drafts a physician-ready appeal letter in five minutes with the right clinical guideline and federal regulation cited. $39 first-level, money back if we can't draft a strong appeal.
Get started →Contact: hello@denialhelp.com